Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

T. Merrill, Joan; Michael Neuwelt, C.; J. Wallace, Daniel; C. Shanahan, Joseph; Latinis, Kevin; C. Oates, Jim; O. Utset, Tammy; Gordon, Caroline; Isenberg, David; Hsieh, Hsin‐Ju; Zhang, David; Brunetta, Paul

doi:10.1002/art.27233

Public

Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

Published in Arthritis & Rheumatism • Dec 28, 2009

Authors:

Joan T. Merrill

C. Michael Neuwelt

Daniel J. Wallace

Abstract

OBJECTIVE: B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in patients with mod...

Subject

Rituximab

Medicine

Azathioprine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!